A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised trials included in the study-design. The pilot study is implemented as a master protocol without study specific interventions, thus as an observational study. The pilot study is for countries/study-groups who intend to join ALLTogether1 (including experimental interventions). For these countries the pilot study is crucial to optimise diagnostics, registration systems, collaborations with vendors, logistics and data-checks before starting the main study. The study only includes "standard of care" treatment included in the master protocol.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowe rozpoznanie białaczki limfoblastycznej (ALL) - typu T-komórkowego lub B-komórkowego potwierdzone w akredytowanym laboratorium
- •Wiek od narodzenia do 45 lat (przed 46. urodzinami) w momencie rozpoznania
- •Pacjent leczony w uczestniczącym ośrodku onkologii dziecięcej lub hematologii
- •Pacjent mieszkający trwale w kraju uczestniczącym w badaniu lub planujący tam pozostać
- •Podpisana świadoma zgoda pacjenta i/lub rodziców/opiekunów prawnych
- •U kobiet w wieku rozrodczym ujemny test ciążowy wykonany maksymalnie 2 tygodnie przed rozpoczęciem leczenia
✗ Disqualifies
- •Niemowlęta poniżej 365 dni życia z białaczką B-komórkową typu KMT2A-rearranged będą skierowane do odpowiedniego innego badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 0 Years
- Maximum age
- 45 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (57)
Aalborg University Hospital, Dept of Paediatrics
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Aarhus University Hospital, Child and Adolescent Health
Aarhus, Denmark
Rigshospitalet, Dept of Haematology
Copenhagen, Denmark
Rigshospitalet, Dept of Paediatrics
Copenhagen, Denmark
Odense University Hospital, Dept of Paediatrics
Odense, Denmark
North Estonia Medical Centre, Dept of Haematology
Tallinn, Estonia
Tallinn Children´s Hospital, Dept of Paediatrics
Tallinn, Estonia
Tartu University Hospital
Tartu, Estonia
Helsinki University Hospital, Dept of Haematology
Helsinki, Finland
Helsinki University Hospital, Dept of Paediatrics
Helsinki, Finland
Kuopio University Hospital, Dept of Haematology
Kuopio, Finland
Kuopio University Hospital, Dept of Paediatrics
Kuopio, Finland
Oulu University Hospital, Dept of Haematology, Dept of Medicine
Oulu, Finland
Oulu University Hospital, Dept of Paediatrics
Oulu, Finland
Tampere University Hospital, Dept of Haematology
Tampere, Finland
Tampere University Hospital, Dept of Paediatrics
Tampere, Finland
Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit
Turku, Finland
Turku University Hospital, Dept of Paediatrics
Turku, Finland
Landspitali University Hospital, Children's Hospital
Reykjavik, Iceland
Children's Hospital, Affiliate of Vilnius University Hospital
Vilnius, Lithuania
Vilnius University Hospital
Vilnius, Lithuania
Haukeland University Hospital, Dept of Haematology
Bergen, Norway
Haukeland University Hospital, Dept of Paediatrics
Bergen, Norway
Oslo University Hospital, Dept of Haematology
Oslo, Norway
Oslo University Hospital, Dept of paediatric haemato- and oncology
Oslo, Norway
Stavanger University Hospital, Dept of Haematology
Stavanger, Norway
University Hospital North Norway, Dept of Haematology
Tromsø, Norway
University Hospital of North Norway, Dept of Paediatrics
Tromsø, Norway
St. Olavs University Hospital, Dept of Paediatrics
Trondheim, Norway
St. Olavs University Hospital, Dept of Haematology
Trondheim, Norway
Hospital Universitario Dr.Balmis
Alicante, Spain
Hospital Universitario de Cruces
Barakaldo, Spain
Hospital Universitario San Joan de Déu
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario La Paz
Fuencarral-El Pardo, Spain
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario Politécnico La Fe
Valencia, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Sahlgrenska University Hospital, Section for Haematology and coagulation
Gothenburg, Sweden
Sahlgrenska University Hospital, Dept of Paediatric Haematology and Oncology
Gothenburg, Sweden
Linköping University Hospital, Dept of Haematology
Linköping, Sweden
Linköping University Hospital, Dept of Paediatrics
Linköping, Sweden
Skåne University Hospital, Dept of Haematology
Lund, Sweden
Skåne University Hospital, Dept of Paediatrics
Lund, Sweden
Örebro University Hospital, Section for Haematology
Örebro, Sweden
Karolinska University Hospital, Dept of Paediatric Oncology and Haematology
Stockholm, Sweden
Karolinska University Hospital, Patient area Haematology
Stockholm, Sweden
Norrland University Hospital, Dept of Haematology
Umeå, Sweden
Norrland University Hospital, Dept of Paediatrics
Umeå, Sweden
Uppsala University Hospital, Dept of Haematology
Uppsala, Sweden
Uppsala University Hospital, Dept of Paediatric Haematology and Oncology
Uppsala, Sweden
Trial contact
Trial Central Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.